Skip to content
ALNY·Nasdaq·US

Alnylam

Alnylam develops and commercializes RNA interference medicines for rare and other diseases. The company generates revenue from approved therapeutics and is building a pipeline of additional RNAi-based drug candidates.

Thematic Position

ALNY

Relationship Groups

Suppliers3
Partners7
Licensing11
Competitors19

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

12 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tarifftrade policyimport restriction
U.S. administration tariffs of 100% or more threatened on pharmaceuticals manufactured outside U.S.
SEC 10-QJul 30, 2026

The full regulatory passage is part of the Pro plan.

24 more · Regulatory and geopolitical insights are part of the Pro plan.